D. Boral Capital reissued their buy rating on shares of ImmunityBio (NASDAQ:IBRX - Free Report) in a report released on Wednesday,Benzinga reports. The firm currently has a $30.00 price objective on the stock.
Other research analysts also recently issued reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price objective on shares of ImmunityBio in a report on Thursday, March 13th. BTIG Research started coverage on ImmunityBio in a research report on Friday, January 10th. They issued a "buy" rating and a $6.00 price target for the company. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, ImmunityBio currently has an average rating of "Buy" and a consensus price target of $12.19.
Check Out Our Latest Research Report on ImmunityBio
ImmunityBio Stock Performance
NASDAQ:IBRX traded up $0.22 during trading hours on Wednesday, reaching $2.85. The stock had a trading volume of 4,669,837 shares, compared to its average volume of 5,736,989. ImmunityBio has a 12-month low of $2.28 and a 12-month high of $10.53. The stock has a 50 day simple moving average of $3.01 and a 200 day simple moving average of $3.53. The stock has a market cap of $2.43 billion, a P/E ratio of -3.10 and a beta of 0.51.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to the consensus estimate of $8.74 million. On average, equities analysts expect that ImmunityBio will post -0.92 earnings per share for the current fiscal year.
Institutional Trading of ImmunityBio
Institutional investors and hedge funds have recently modified their holdings of the business. Stephens Inc. AR purchased a new stake in ImmunityBio in the fourth quarter valued at approximately $26,000. Thrive Wealth Management LLC bought a new position in shares of ImmunityBio in the 1st quarter worth $30,000. Cibc World Markets Corp purchased a new stake in shares of ImmunityBio during the 4th quarter valued at $35,000. Maia Wealth LLC bought a new stake in shares of ImmunityBio during the 4th quarter worth $37,000. Finally, GF Fund Management CO. LTD. purchased a new position in ImmunityBio in the fourth quarter worth $37,000. Hedge funds and other institutional investors own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Further Reading
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
